HAVN Life Sciences Inc.
HAVLF
$0.001
$0.000.00%
OTC PK
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 843.93% | 1,515.88% | 3,371.05% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 843.93% | 1,515.88% | 3,371.05% | -- | -- |
| Cost of Revenue | 849.35% | 1,377.65% | 4,065.12% | -- | -- |
| Gross Profit | 834.30% | 1,702.38% | 2,466.67% | -- | -- |
| SG&A Expenses | -73.20% | -70.65% | -58.68% | -50.52% | -- |
| Depreciation & Amortization | -94.07% | -92.35% | -90.07% | -87.30% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -73.11% | -71.90% | -63.40% | -55.79% | -- |
| Operating Income | 76.78% | 75.05% | 65.05% | 57.26% | -- |
| Income Before Tax | 30.29% | 48.35% | 35.93% | 24.63% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.29% | 48.35% | 35.93% | 24.63% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.29% | 48.35% | 35.93% | 24.63% | -- |
| EBIT | 76.78% | 75.05% | 65.05% | 57.26% | -- |
| EBITDA | 72.07% | 70.03% | 58.24% | 46.01% | -- |
| EPS Basic | 51.48% | 67.72% | 63.98% | 61.30% | -- |
| Normalized Basic EPS | 83.70% | 87.06% | 84.35% | 80.73% | -- |
| EPS Diluted | 52.06% | 67.94% | 63.35% | 60.70% | -- |
| Normalized Diluted EPS | 83.70% | 87.06% | 84.35% | 80.73% | -- |
| Average Basic Shares Outstanding | 68.46% | 49.36% | 66.25% | 118.42% | -- |
| Average Diluted Shares Outstanding | 68.46% | 49.36% | 66.25% | 118.42% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |